Table 1. Baseline demographic and clinical data of cardiovascular older adults undergoing 6-months supplementation of calcifediol in daily drops.
| (n = 47) | |
| Age, yrs | 70.23 ± 8.41 (53.00; 90.00) |
| Gender (male/female) | 20 (43%) / 27 (57%) |
| Body mass index, kg/m2 | 30.25 ± 5.13 (20.54; 42.06) |
| Number of cardiovascular diseases | 2.00 (1.00/2.00) |
| High blood pressure | 37 (79%) |
| Ischaemic heart disease | 4 (8%) |
| Arrhythmia | 5 (11%) |
| Heart valve problem | 1 (2%) |
| Vascular disease | 6 (13%) |
| Number of comorbidities | 1.00 (0.00/2.00) |
| Obesity | 21 (45%) |
| Dyslipidaemia | 15 (32%) |
| Diabetes mellitus type 2 | 8 (17%) |
| Number of medications | 3.00 (2.00/5.00) |
| Beta-blockers | 18 (38%) |
| Ca blockers | 12 (26%) |
| ACEi/ARB/DRI | 32 (68%) |
| Diuretics | 22 (47%) |
| Anti-platelet, anti-integrin, anti-thrombotic | 12 (26%) |
| Anti-arrhythmics | 5 (11%) |
| 25 [OH] D, ng/mL | 16.33 ± 7.26 (4.90; 30.10) |
| Left ventricular ejection fraction, % | 62.26 ± 4.29 (52.00; 70.00) |
| Global longitudinal strain, % | −18.17 ± 1.75 (−11.90; −22.80) |
Continuous variables were reported as mean ± SD (min; max) or as median (Q1/Q3). Categorical variables were reported as frequencies and percentages. ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blockers; DRI: direct renin inhibitor.